- Home
- CRDL vs NIM Comparison
CRDL vs NIM Comparison
Compare CRDL & NIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- NIM
- Stock Information
- Founded
- CRDL 2017
- NIM 1992
- Country
- CRDL Canada
- NIM United States
- Employees
- CRDL N/A
- NIM N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- NIM Trusts Except Educational Religious and Charitable
- Sector
- CRDL Health Care
- NIM Finance
- Exchange
- CRDL Nasdaq
- NIM Nasdaq
- Market Cap
- CRDL 126.5M
- NIM 114.3M
- IPO Year
- CRDL N/A
- NIM N/A
- Fundamental
- Price
- CRDL $1.31
- NIM $9.18
- Analyst Decision
- CRDL Strong Buy
- NIM
- Analyst Count
- CRDL 2
- NIM 0
- Target Price
- CRDL $9.00
- NIM N/A
- AVG Volume (30 Days)
- CRDL 1.2M
- NIM 35.4K
- Earning Date
- CRDL 08-26-2025
- NIM 01-01-0001
- Dividend Yield
- CRDL N/A
- NIM 3.46%
- EPS Growth
- CRDL N/A
- NIM N/A
- EPS
- CRDL N/A
- NIM N/A
- Revenue
- CRDL N/A
- NIM N/A
- Revenue This Year
- CRDL N/A
- NIM N/A
- Revenue Next Year
- CRDL N/A
- NIM N/A
- P/E Ratio
- CRDL N/A
- NIM N/A
- Revenue Growth
- CRDL N/A
- NIM N/A
- 52 Week Low
- CRDL $0.77
- NIM $8.28
- 52 Week High
- CRDL $2.63
- NIM $9.74
- Technical
- Relative Strength Index (RSI)
- CRDL 51.92
- NIM 60.08
- Support Level
- CRDL $0.94
- NIM $9.10
- Resistance Level
- CRDL $1.55
- NIM $9.18
- Average True Range (ATR)
- CRDL 0.13
- NIM 0.07
- MACD
- CRDL -0.00
- NIM 0.01
- Stochastic Oscillator
- CRDL 59.74
- NIM 90.00
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About NIM Nuveen Select Maturities Municipal Fund
Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its primary investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital. Its secondary investment objective is to enhance portfolio value relative to the municipal bond market through investments in tax-exempt municipal obligations that are underrated or undervalued, or that represent municipal market sectors that are undervalued.